PLASMA CELL MYELOMA

This phase 2 trial tests a combination of belantamab mafodotin, pomalidomide, and dexamethasone as maintenance therapy for people with high-risk multiple myeloma who have already had a stem cell transplant. The goal is to see if this three-drug mix can kill remaining cancer cells…

This study compares a four-drug combination (daratumumab, bortezomib, lenalidomide, and dexamethasone) against a three-drug combination (daratumumab, lenalidomide, and dexamethasone) in people newly diagnosed with multiple myeloma who are not eligible for early stem cell transpla…

This early-stage study tests a new radioactive tracer called [89Zr]DFO-YS5 for PET scans to find multiple myeloma cells that have a specific protein (CD46). About 20 adults with confirmed multiple myeloma will receive the tracer and have a PET scan. The goal is to see if this met…

This early trial is testing whether loratadine, better known as the allergy medicine Claritin, can reduce bone pain caused by a drug called G-CSF in people with multiple myeloma who are having their stem cells collected. The study will compare pain levels between those taking lor…

This study tests whether a very low dose of radiation (2 Gy) can relieve bone pain in people with multiple myeloma that has spread to the bones. The goal is to see if this gentler approach works as well as standard radiation but with fewer side effects and less disruption to chem…

This study looks at whether non-chemo approaches like physical activity, intermittent fasting, or adding a beta-blocker (propranolol) can improve immune function and quality of life in people with multiple myeloma or related blood disorders. Researchers will measure changes in im…

This study tracks memory and thinking changes in 100 adults with blood cancers who receive whole brain radiation. Researchers will test cognitive skills like recall and attention over time. The goal is to better understand the mental side effects of this treatment, not to change …